The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
This strategic decision will unlock significant value for our scientific and industrial products business
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
Subscribe To Our Newsletter & Stay Updated
